PepGen (PEPG) Cash from Restructuring (2022 - 2025)

PepGen (PEPG) posted Cash from Restructuring of -$11000.0 for Q2 2025, down 200.0% sequentially from $11000.0 in Q1 2025.

PepGen (PEPG) Cash from Restructuring (2022 - 2025) Analysis & Trends

PepGen has reported Cash from Restructuring for 3 years, with the latest figure at -$11000.0 in Q2 2025.

Quarterly Cash from Restructuring changed N/A year-over-year to -$11000.0 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was $50000.0 (up 177.78% YoY) and the FY2024 annual result came in at $70000.0, changed N/A from the prior year.
Cash from Restructuring fell to -$11000.0 in Q2 2025 per PEPG's latest filing, from $11000.0 in the prior quarter.
Over five years, Cash from Restructuring peaked at $50000.0 in Q4 2024 and troughed at -$11000.0 in Q2 2025.
A 3-year average of $13600.0 and a median of $11000.0 in 2025 frame the typical range for Cash from Restructuring.
The widest YoY moves for Cash from Restructuring: up 45.0% in 2025, down 45.0% in 2025.
Over 3 years, Cash from Restructuring stood at -$2000.0 in 2022, then surged by 2600.0% to $50000.0 in 2024, then sank by 122.0% to -$11000.0 in 2025.
According to Business Quant data, Cash from Restructuring over the past three periods registered -$11000.0, $11000.0, and $50000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	PepGen	207.09 Mn	207.09 Mn	-

Download Data